NCT00478959View on ClinicalTrials.gov

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Hodgkin Disease

Interventions

DRUG

Lenalidomide (Revlimid®)

25mg PO daily for 21 out of 28days per cycle

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University Health Network, Toronto

OTHER